FDA Speeds Up Eye Drug for Rare Kids' Disease with Magic Voucher
Published Date: 3/13/2026
Notice
Summary
The FDA just approved EYLEA HD (aflibercept) using a special Rare Pediatric Disease Priority Review Voucher, speeding up its review because it treats a rare childhood illness. This means the company behind EYLEA HD got a fast-track pass, helping kids get medicine sooner. Keep an eye out for more rare disease treatments moving faster thanks to this program!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Faster Approval for Rare Pediatric Drug
If you have a child with the rare pediatric condition treated by EYLEA HD, the FDA approved EYLEA HD (aflibercept) using a Rare Pediatric Disease Priority Review Voucher. The supplemental application was approved on November 19, 2025, and the voucher sped up the review so children can access the medicine sooner.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in